Microviable Therapeutics Announces 1.5 Million Euros Investment to Advance the Company´s Microbiota-Derived Biotherapeutic Products
Microviable Therapeutics SL, a preclinical stage biotechnology company developing orally administered biological drugs based on microbiota-derived products, announced 1.5 million euros seed funding from the private medical group Inmunomet Intolerancia y Disbiosis SL.
Microviable will use the seed funding to enhance their therapeutic development platform and advance their pipeline to the clinical stage. The lead product, MVT-201, is under evaluation at pre-clinical stage with positive results, and it is an unique in its kind biological drug based on complete microbiota (HiPMTM) for undisclosed targets. The microbiota-derived product development platform also includes rationally design and defined bacterial consortia that will be advanced with this funding.
This investment will enable to consolidate Microviable’s growth and focus towards the therapeutics, while increasing their facilities and headcount.
“We are really excited for Microviable´s future and grateful for this opportunity to bring novel solutions to healthcare with the ultimate goal of improving the patients’ quality of life”, said Claudio Hidalgo Cantabrana, PhD, co-founder and CEO at Microviable. “We wanted a strategic partner that shares our vision of using microbiota-derived biological drugs to treat patients while providing smart capital, and Inmunomet fulfills all of our expectations”.
Inmunomet is a private medical group specialized in intolerances and gut dysbiosis related disorders with strong experience on the clinic. With this investment, Inmunomet is seeking to be part of Microviable´s growth being ahead on the development of novel solutions based on microbiota-derived biotherapeutic products. Inmunomet provides not only the funding but smart capital and synergies on the clinic, very well aligned with Microviable focus and providing access to the real-world clinical needs to address unmet challenges in human health.
Microviable Therapeutics SL, spun out from the Spanish National Research Council in 2016, focused on developing novel technologies and therapeutic products from the microbiota. Over the last years, Microviable lunched a disruptive product for microbiota sampling that has grown exponentially into an international market with clients across fifteen different countries. Moreover, it has developed a unique technology to store human microbiota for downstream therapeutic applications. Currently, Microviable’s platform together with its large and diverse proprietary bacterial culture collection, has enabled the development of two different products, a unique in its kind product of complete microbiota and rationally defined bacterial consortia.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Claudio Hidalgo Cantabrana, PhD
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
GC Aesthetics® Announces the Launch of FixNip™: a Total Game-Changer in Breast Reconstruction17.5.2022 17:15:00 EEST | Press release
GC Aesthetics®, Inc. (GCA), a privately-held medical technology company providing Healthcare Aesthetic Solutions, announced the launch of an Innovative Nipple Areola Complex (NAC) Reconstruction Implant : FixNip™ NRI. This unrivalled medical device is the answer to a well-known clinical need of thousands of women around the world. Until now, a variety of surgical techniques are used to try to reconstruct the nipple areola complex with none providing a long term aesthetic solution. GC Aesthetics® in an exclusive partnership agreement with FixNip LTD is proud of launching FixNip NRI in main European Territories, while the roll-out to Latin America, Central Europe and Asia will be announced later this year. "We are committed to deliver safe options that establish a newer, higher, and more beneficial standard of care for women who seek to total breast reconstruction. Such technology breakthrough will complete our range of solutions dedicated to women aesthetic healthcare. FixNip by GC Aest
Enry’s Island Secures €20 Million from LDA Capital to Scale the First Accelerator in the Metaverse17.5.2022 17:00:00 EEST | Press release
Enry’s Island is delighted to announce that they have secured a Euro 20 million capital commitment from LDA Capital, an alternative investment group with expertise in complex, cross-border transactions around the globe, based in Los Angeles, California. Adding to the year’s success, this capital commitment comes just as Enry’s Island prepares to operate on international markets, making them a rising star in the incubation and acceleration world, one of the hottest industries of this current economic environment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220517005729/en/ LDA Capital lands on Enry's Island, with a € 20M round (Graphic: Business Wire) “We are excited about our partnership with LDA Capital”, says Luigi Valerio Rinaldi, founder and CEO of Enry’s Island. Over the course of the next few months, the Company will transform into a “S.p.a.” (Italian joint stock company), “allowing the business to scale even faster
Regulatory Framework for E-cigarettes Essential in Moroccan and Algerian Markets as Prevalence of Smoking Expected to Rise Notably By 202517.5.2022 16:26:00 EEST | Press release
RELX International, a responsible multinational electronic cigarettes company, is urging decision-makers in Morocco and Algeria to roll out comprehensive regulatory frameworks for e-cigarettes, ahead of an expected surge in smoking habits. Longstanding research has shown that smoking traditional, tobacco-based cigarettes poses significant health risks. According to data compiled by website GSTHR.org (Global State of Tobacco Harm Reduction), there has been an upward trend in current smoking prevalence in the general population in Morocco. In 2015, overall prevalence was estimated to be 23%, with a projection to increase to 28% by 2025 in Morocco. . While in Algeria, current smoking trends for the overall adult population is also projected to increase, with an estimate of 16.9% by 2025 as per GSTHR.org. . In contrast to traditional cigarettes, e-cigarettes are increasingly being hailed as a better alternative and can even help adult smokers reduce or quit smoking entirely according
Oregon Tool Celebrates 75th Anniversary17.5.2022 16:22:00 EEST | Press release
In 1947, forester Joe Cox observed the C-shaped jaws of a timber beetle larva deftly chewing through wood. This was the inspiration for his “Cox Chipper Chain,” which he quietly invented in the basement of his home in Portland, Oregon. That same year, Cox started the Oregon Saw Chain Corp. to produce his saw chain – from a basement startup to a global manufacturer. Over time, Cox and his saw chain revolutionized the timber industry, and today the company he founded is the manufacturer of the World’s #1 Saw Chain™. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220511005669/en/ Oregon Tool 75th Anniversary: Seeding the Roots of Our Future. (Graphic: Business Wire) The company – known today as Oregon Tool – has grown into a multinational organization with numerous acquisitions and mergers. At 3,000 Team Members strong, Oregon Tool sells thousands of products in more than 110 countries. Oregon Tool is a top manufacturer of saw
Smokers and the Business Environment in Jordan Will Benefit Significantly From Government Reforms on E-Cigarette Policies and Taxes17.5.2022 16:14:00 EEST | Press release
RELX International, a responsible multinational electronic cigarettes company, is continuing its support for the Hashemite Kingdom of Jordan to adopt a more favourable fiscal policy when it comes to the country’s e-cigarette polices and taxes. Should policies and taxes on these products be revised in line with regional markets such as Egypt, Kuwait, Saudi Arabia and the UAE, Jordanian adult smokers, the business environment and government financial reserves will benefit greatly. According to the Jordan National Stepwise Survey (STEPs) for Noncommunicable Diseases Risk Factors 2019, adult smokers in Jordan smoke an average of 21.3 cigarettes a day . The rate is said to be amongst the highest in the world, with worldwide scientific research linking high tobacco use to a raft of diseases. In contrast, an increasing number of reputed organisations including the UK’s National Health Service (NHS) has said that e-cigarettes are far less harmful than traditional cigarettes, and can actuall
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom